PDS Biotechnology Corp
NASDAQ:PDSB
Balance Sheet
Balance Sheet Decomposition
PDS Biotechnology Corp
Current Assets | 68.7m |
Cash & Short-Term Investments | 66.6m |
Other Current Assets | 2.1m |
Non-Current Assets | 320.6k |
PP&E | 320.6k |
Current Liabilities | 15.1m |
Accounts Payable | 6m |
Accrued Liabilities | 1.7m |
Other Current Liabilities | 7.3m |
Non-Current Liabilities | 16.8m |
Long-Term Debt | 16.8m |
Balance Sheet
PDS Biotechnology Corp
Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||
Cash & Cash Equivalents |
14
|
130
|
106
|
88
|
35
|
12
|
29
|
65
|
74
|
57
|
|
Cash Equivalents |
14
|
130
|
106
|
88
|
35
|
12
|
29
|
65
|
74
|
57
|
|
Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Current Assets |
2
|
1
|
1
|
1
|
1
|
2
|
2
|
2
|
3
|
2
|
|
Total Current Assets |
15
|
131
|
107
|
89
|
36
|
15
|
30
|
67
|
77
|
59
|
|
PP&E Net |
1
|
3
|
3
|
3
|
0
|
0
|
1
|
0
|
1
|
0
|
|
PP&E Gross |
1
|
3
|
3
|
3
|
0
|
0
|
1
|
0
|
1
|
0
|
|
Accumulated Depreciation |
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Assets |
17
N/A
|
134
+689%
|
111
-17%
|
93
-17%
|
36
-61%
|
15
-60%
|
31
+113%
|
67
+117%
|
77
+15%
|
59
-23%
|
|
Liabilities | |||||||||||
Accounts Payable |
2
|
3
|
4
|
4
|
0
|
1
|
1
|
1
|
1
|
7
|
|
Accrued Liabilities |
2
|
4
|
3
|
5
|
0
|
1
|
2
|
2
|
9
|
2
|
|
Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Current Portion of Long-Term Debt |
0
|
2
|
0
|
3
|
0
|
0
|
0
|
0
|
0
|
4
|
|
Other Current Liabilities |
0
|
0
|
0
|
0
|
6
|
1
|
0
|
0
|
0
|
0
|
|
Total Current Liabilities |
4
|
9
|
7
|
13
|
6
|
3
|
3
|
4
|
10
|
14
|
|
Long-Term Debt |
3
|
3
|
15
|
17
|
0
|
0
|
0
|
0
|
23
|
20
|
|
Other Liabilities |
2
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
Total Liabilities |
8
N/A
|
12
+43%
|
22
+86%
|
30
+40%
|
6
-79%
|
3
-56%
|
4
+36%
|
4
+5%
|
33
+725%
|
33
+1%
|
|
Equity | |||||||||||
Common Stock |
37
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Retained Earnings |
30
|
62
|
101
|
152
|
193
|
29
|
44
|
61
|
102
|
145
|
|
Additional Paid In Capital |
2
|
185
|
190
|
214
|
223
|
41
|
71
|
124
|
146
|
171
|
|
Total Equity |
9
N/A
|
123
+1 261%
|
89
-27%
|
62
-30%
|
30
-52%
|
12
-61%
|
27
+132%
|
63
+133%
|
44
-30%
|
26
-41%
|
|
Total Liabilities & Equity |
17
N/A
|
134
+689%
|
111
-17%
|
93
-17%
|
36
-61%
|
15
-60%
|
31
+113%
|
67
+117%
|
77
+15%
|
59
-23%
|
|
Shares Outstanding | |||||||||||
Common Shares Outstanding |
1
|
1
|
1
|
2
|
2
|
5
|
22
|
28
|
30
|
33
|